RecruitingNCT05024929

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

Targeted Therapy to Increase RAI Uptake in Patients With Metastatic Differentiated Thyroid Cancer

Sponsor

Children's Hospital of Philadelphia

Enrollment

32 participants

Start Date

Jul 16, 2021

Study Type

OBSERVATIONAL

Conditions

Pediatric Cancer Papillary Thyroid Cancer Differentiated Thyroid Cancer

Summary

Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.

Eligibility

Min Age: 0 Years

Plain Language Summary

Simplified for easier understanding

This study looks at whether targeted therapies — drugs that attack specific gene mutations — can help thyroid cancer tumors absorb radioactive iodine (RAI) treatment better. Many thyroid cancers stop responding to RAI over time; targeted drugs may be able to "re-sensitize" the tumors. **You may be eligible if...** - You have been diagnosed with differentiated thyroid cancer (a common type) - Your tumor has a specific gene mutation or fusion (such as NTRK, RET, ALK, or BRAF) identified in a certified lab - You have measurable spread to the lungs visible on CT scan - You are already planned to receive a targeted therapy drug (commercially or via another trial) **You may NOT be eligible if...** - Your thyroid cancer does not have one of the targetable gene changes - You do not have measurable lung involvement - You are unable to undergo imaging or the required study procedures Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREWhole body scan

Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND). During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor.